Baseline biomarkers in patients in PROWESS by Leiden mutation status
. | Normal range . | VL+/- patients (N = 65) . | . | VL-/- patients (N = 1536) . | . | ||
|---|---|---|---|---|---|---|---|
| Biomarkers . | . | No. . | Median (95% Cl) . | No. . | Median (95% Cl) . | ||
| Procoagulant markers | |||||||
| D-dimer, μg/mL | 0.0-39 | 62 | 3.8 (3.1-5.9) | 1413 | 4.2 (4.0-4.5) | ||
| TAT, μg/L | 1-4.1 | 23 | 9.8 (6.3-16.6) | 356 | 11.1 (10.3-12.6) | ||
| F1.2, nM | 0.44-1.1 | 22 | 1.8 (1.2-2.2) | 356 | 1.8 (1.5-1.9) | ||
| Anticoagulant factors | |||||||
| Protein C, % | 81-173 | 63 | 49 (40-60) | 1435 | 48 (46-50) | ||
| Protein S, % | 60-155 | 61 | 36 (28-50) | 1404 | 37 (35-39) | ||
| Antithrombin, % | 80-120 | 62 | 63 (56-70) | 1421 | 59 (58-61) | ||
| Global coagulation tests | |||||||
| Platelet counts, 109/L | 140-400 | 59 | 172 (145-212) | 1300 | 183 (178-188) | ||
| PT, s | 10.6-14.5 | 62 | 18.2 (17.2-18.8) | 1420 | 18.7 (18.4-18.9) | ||
| APTT, s | 21-39 | 61 | 42.0 (39.2-46.6) | 1425 | 42.4 (41.9-43.2) | ||
| Fibrinolytic factors | |||||||
| PAI-1, AU/mL | 4-37.8 | 18 | 27 (16-38) | 267 | 34 (30-37) | ||
| TAFI, μg/mL | 2.8-9.2 | 19 | 6.3 (4.0-8.5) | 287 | 4.6 (4.3-5.0) | ||
| α2-AP, % | 80-120 | 19 | 102 (80-120) | 287 | 96 (92-103) | ||
| Plasminogen, % | 64-111 | 19 | 57 (51-77) | 284 | 60 (58-63) | ||
| Endothelial injury marker | |||||||
| sTM, ng/mL | 18-53 | 19 | 97 (71-134) | 282 | 72 (66-78) | ||
| Inflammatory marker | |||||||
| IL-6, pg/mL | 0.38-10.1 | 65 | 474 (232-1051) | 1489 | 494 (427-558) | ||
. | Normal range . | VL+/- patients (N = 65) . | . | VL-/- patients (N = 1536) . | . | ||
|---|---|---|---|---|---|---|---|
| Biomarkers . | . | No. . | Median (95% Cl) . | No. . | Median (95% Cl) . | ||
| Procoagulant markers | |||||||
| D-dimer, μg/mL | 0.0-39 | 62 | 3.8 (3.1-5.9) | 1413 | 4.2 (4.0-4.5) | ||
| TAT, μg/L | 1-4.1 | 23 | 9.8 (6.3-16.6) | 356 | 11.1 (10.3-12.6) | ||
| F1.2, nM | 0.44-1.1 | 22 | 1.8 (1.2-2.2) | 356 | 1.8 (1.5-1.9) | ||
| Anticoagulant factors | |||||||
| Protein C, % | 81-173 | 63 | 49 (40-60) | 1435 | 48 (46-50) | ||
| Protein S, % | 60-155 | 61 | 36 (28-50) | 1404 | 37 (35-39) | ||
| Antithrombin, % | 80-120 | 62 | 63 (56-70) | 1421 | 59 (58-61) | ||
| Global coagulation tests | |||||||
| Platelet counts, 109/L | 140-400 | 59 | 172 (145-212) | 1300 | 183 (178-188) | ||
| PT, s | 10.6-14.5 | 62 | 18.2 (17.2-18.8) | 1420 | 18.7 (18.4-18.9) | ||
| APTT, s | 21-39 | 61 | 42.0 (39.2-46.6) | 1425 | 42.4 (41.9-43.2) | ||
| Fibrinolytic factors | |||||||
| PAI-1, AU/mL | 4-37.8 | 18 | 27 (16-38) | 267 | 34 (30-37) | ||
| TAFI, μg/mL | 2.8-9.2 | 19 | 6.3 (4.0-8.5) | 287 | 4.6 (4.3-5.0) | ||
| α2-AP, % | 80-120 | 19 | 102 (80-120) | 287 | 96 (92-103) | ||
| Plasminogen, % | 64-111 | 19 | 57 (51-77) | 284 | 60 (58-63) | ||
| Endothelial injury marker | |||||||
| sTM, ng/mL | 18-53 | 19 | 97 (71-134) | 282 | 72 (66-78) | ||
| Inflammatory marker | |||||||
| IL-6, pg/mL | 0.38-10.1 | 65 | 474 (232-1051) | 1489 | 494 (427-558) | ||